BIOCON :

• Started in 1978
• Asia’s largest Biopharma research hub in Bangalore SEZ.
• Main products : Statins and Insulin
• Products for Diabetology, Cardiology, Imunotherapy, Oncotherapeutics and nephrology.
• Setting up biopharma manufacturing and R&D facility in Malaysia – to be commissioned in 2015.
• 2.6 times rise in turnover in last 7 years
• 2 times increase in profit in last 7 years
• FY 2012 turnover : 2086.5 Crores.
• Debt equity ratio of 0.10 for FY 2012
• 56.5% of revenue from Domestic market, 43.5% from exports
• Aims to become US$ 1 billion company by FY 2018
• Focusing on Small molecules, Biosimilars, Branded formulations, Novel molecules and research services.
• SYNGENE – subsidiary – contract research. – May be listed in future.
•  GE capital invested Rs.125 crores for 7.69% stake in Syngene – valuing the subsidiary company @ Rs.1625 Crores.